Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

BACKGROUND AND OBJECTIVE: Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has demonstrated efficacy as a first-line treatment for chronic lymphocytic leukemia in multiple, phase III, randomized clinical trials. This systematic literature review assessed the clinical effectiveness of ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Philip, Kistler, Kristin D., Douyon, Luc, Volodarsky, Raisa, Young, Alex, Karve, Sudeep, Challagulla, Swetha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943824/
https://www.ncbi.nlm.nih.gov/pubmed/36534239
http://dx.doi.org/10.1007/s40801-022-00332-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943824/
https://www.ncbi.nlm.nih.gov/pubmed/36534239
http://dx.doi.org/10.1007/s40801-022-00332-4

Ejemplares similares